BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 18782781)

  • 1. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG
    Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tricuspid valve endocarditis with daptomycin and linezolid therapy.
    Galanter KM; Ho J
    Am J Health Syst Pharm; 2019 Jul; 76(14):1033-1036. PubMed ID: 31201773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
    Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
    Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.
    Johnson TM; Molina KC; Miller MA; Kiser TH; Huang M; Mueller SW
    Int J Antimicrob Agents; 2021 Apr; 57(4):106310. PubMed ID: 33609718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
    Barber KE; Rybak MJ; Sakoulas G
    J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
    [No Abstract]   [Full Text] [Related]  

  • 9. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
    Ruiz J; Ramirez P; Concha P; Salavert-Lletí M; Villarreal E; Gordon M; Frasquet J; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Sep; 14():141-144. PubMed ID: 29601996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
    Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
    Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S
    Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
    Holubar M; Meng L; Alegria W; Deresinski S
    Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.
    Tong SY; Nelson J; Paterson DL; Fowler VG; Howden BP; Cheng AC; Chatfield M; Lipman J; Van Hal S; O'Sullivan M; Robinson JO; Yahav D; Lye D; Davis JS;
    Trials; 2016 Mar; 17():170. PubMed ID: 27029920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
    Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the minimum inhibitory concentration of daptomycin on the outcomes of Staphylococcus aureus bacteraemia.
    AlQahtani H; Baloch S; Aleanizy FS; Alqahtani FY; Tabb D
    J Glob Antimicrob Resist; 2021 Mar; 24():23-26. PubMed ID: 33279686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
    Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
    JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.
    Tenover FC; Sinner SW; Segal RE; Huang V; Alexandre SS; McGowan JE; Weinstein MP
    Int J Antimicrob Agents; 2009 Jun; 33(6):564-8. PubMed ID: 19233622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
    Mohan SS; McDermott BP; Cunha BA
    Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.